TY - JOUR AU - Tivol, E. A. AU - Borriello, F. AU - Schweitzer, A. N. AU - Lynch, W. P. AU - Bluestone, J. A. AU - Sharpe, A. H. PY - 1995 DA - 1995// TI - Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 JO - Immunity VL - 3 UR - https://doi.org/10.1016/1074-7613(95)90125-6 DO - 10.1016/1074-7613(95)90125-6 ID - Tivol1995 ER - TY - JOUR AU - Fife, B. T. AU - Pauken, K. E. AU - Eagar, T. N. AU - Obu, T. AU - Wu, J. AU - Tang, Q. PY - 2009 DA - 2009// TI - Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal JO - Nat Immunol VL - 10 UR - https://doi.org/10.1038/ni.1790 DO - 10.1038/ni.1790 ID - Fife2009 ER - TY - JOUR AU - Esensten, J. H. AU - Helou, Y. A. AU - Chopra, G. AU - Weiss, A. AU - Bluestone, J. A. PY - 2016 DA - 2016// TI - CD28 costimulation: from mechanism to therapy JO - Immunity VL - 44 UR - https://doi.org/10.1016/j.immuni.2016.04.020 DO - 10.1016/j.immuni.2016.04.020 ID - Esensten2016 ER - TY - JOUR AU - Krummel, M. F. AU - Allison, J. P. PY - 1995 DA - 1995// TI - CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation JO - J Exp Med VL - 182 UR - https://doi.org/10.1084/jem.182.2.459 DO - 10.1084/jem.182.2.459 ID - Krummel1995 ER - TY - JOUR AU - Quezada, S. A. AU - Peggs, K. S. PY - 2013 DA - 2013// TI - Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer JO - Br J Cancer VL - 108 UR - https://doi.org/10.1038/bjc.2013.117 DO - 10.1038/bjc.2013.117 ID - Quezada2013 ER - TY - JOUR AU - Brunner, M. C. AU - Chambers, C. A. AU - Chan, F. K. AU - Hanke, J. AU - Winoto, A. AU - Allison, J. P. PY - 1999 DA - 1999// TI - CTLA-4-mediated inhibition of early events of T cell proliferation JO - J Immunol VL - 162 ID - Brunner1999 ER - TY - JOUR AU - Thibult, M. -. L. AU - Mamessier, E. AU - Gertner-Dardenne, J. AU - Pastor, S. AU - Just-Landi, S. AU - Xerri, L. PY - 2013 DA - 2013// TI - PD-1 is a novel regulator of human B-cell activation JO - Int Immunol VL - 25 UR - https://doi.org/10.1093/intimm/dxs098 DO - 10.1093/intimm/dxs098 ID - Thibult2013 ER - TY - JOUR AU - Liu, Y. AU - Cheng, Y. AU - Xu, Y. AU - Wang, Z. AU - Du, X. AU - Li, C. PY - 2017 DA - 2017// TI - Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers JO - Oncogene VL - 36 UR - https://doi.org/10.1038/onc.2017.209 DO - 10.1038/onc.2017.209 ID - Liu2017 ER - TY - JOUR AU - Freeman, G. J. AU - Long, A. J. AU - Iwai, Y. AU - Bourque, K. AU - Chernova, T. AU - Nishimura, H. PY - 2000 DA - 2000// TI - Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation JO - J Exp Med VL - 192 UR - https://doi.org/10.1084/jem.192.7.1027 DO - 10.1084/jem.192.7.1027 ID - Freeman2000 ER - TY - JOUR AU - Brown, J. A. AU - Dorfman, D. M. AU - Ma, F. -. R. AU - Sullivan, E. L. AU - Munoz, O. AU - Wood, C. R. PY - 2003 DA - 2003// TI - Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production JO - J Immunol VL - 170 UR - https://doi.org/10.4049/jimmunol.170.3.1257 DO - 10.4049/jimmunol.170.3.1257 ID - Brown2003 ER - TY - JOUR AU - Iwai, Y. AU - Ishida, M. AU - Tanaka, Y. AU - Okazaki, T. AU - Honjo, T. AU - Minato, N. PY - 2002 DA - 2002// TI - Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade JO - Proc Natl Acad Sci U S A VL - 99 UR - https://doi.org/10.1073/pnas.192461099 DO - 10.1073/pnas.192461099 ID - Iwai2002 ER - TY - JOUR AU - Topalian, S. L. AU - Drake, C. G. AU - Pardoll, D. M. PY - 2012 DA - 2012// TI - Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity JO - Curr Opin Immunol VL - 2 UR - https://doi.org/10.1016/j.coi.2011.12.009 DO - 10.1016/j.coi.2011.12.009 ID - Topalian2012 ER - TY - JOUR AU - Hodi, F. S. AU - O’Day, S. J. AU - McDermott, D. F. AU - Weber, R. W. AU - Sosman, J. A. AU - Haanen, J. B. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Sharma, P. AU - Allison, J. P. PY - 2015 DA - 2015// TI - The future of immune checkpoint therapy JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa8172 DO - 10.1126/science.aaa8172 ID - Sharma2015 ER - TY - JOUR AU - Massard, C. AU - Gordon, M. S. AU - Sharma, S. AU - Rafii, S. AU - Wainberg, Z. A. AU - Luke, J. PY - 2016 DA - 2016// TI - Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.67.9761 DO - 10.1200/JCO.2016.67.9761 ID - Massard2016 ER - TY - JOUR AU - Powles, T. AU - Durán, I. AU - Heijden, M. S. AU - Loriot, Y. AU - Vogelzang, N. J. AU - Giorgi, U. PY - 2018 DA - 2018// TI - Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial JO - Lancet VL - 391 UR - https://doi.org/10.1016/S0140-6736(17)33297-X DO - 10.1016/S0140-6736(17)33297-X ID - Powles2018 ER - TY - JOUR AU - Le, D. T. AU - Uram, J. N. AU - Wang, H. AU - Bartlett, B. R. AU - Kemberling, H. AU - Eyring, A. D. PY - 2015 DA - 2015// TI - PD-1 blockade in tumors with mismatch-repair deficiency JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1500596 DO - 10.1056/NEJMoa1500596 ID - Le2015 ER - TY - JOUR AU - Larkin, J. AU - Chiarion-Sileni, V. AU - Gonzalez, R. AU - Grob, J. J. AU - Cowey, C. L. AU - Lao, C. D. PY - 2015 DA - 2015// TI - Combined nivolumab and ipilimumab or monotherapy in untreated melanoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504030 DO - 10.1056/NEJMoa1504030 ID - Larkin2015 ER - TY - JOUR AU - Topalian, S. L. AU - Hodi, F. S. AU - Brahmer, J. R. AU - Gettinger, S. N. AU - Smith, D. C. AU - McDermott, D. F. PY - 2012 DA - 2012// TI - Safety, activity, and immune correlates of anti-PD-1 antibody in cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1200690 DO - 10.1056/NEJMoa1200690 ID - Topalian2012 ER - TY - JOUR AU - Tarhini, A. PY - 2013 DA - 2013// TI - Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management JO - Scientifica (Cairo) VL - 2013 ID - Tarhini2013 ER - TY - JOUR AU - Rizvi, N. A. AU - Hellmann, M. D. AU - Snyder, A. AU - Kvistborg, P. AU - Makarov, V. AU - Havel, J. J. PY - 2015 DA - 2015// TI - Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa1348 DO - 10.1126/science.aaa1348 ID - Rizvi2015 ER - TY - JOUR AU - Taube, J. M. AU - Klein, A. AU - Brahmer, J. R. AU - Xu, H. AU - Pan, X. AU - Kim, J. H. PY - 2014 DA - 2014// TI - Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-3271 DO - 10.1158/1078-0432.CCR-13-3271 ID - Taube2014 ER - TY - JOUR AU - Gandini, S. AU - Massi, D. AU - Mandalà, M. PY - 2016 DA - 2016// TI - PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematic review and meta-analysis JO - Crit Rev Oncol Hematol VL - 100 UR - https://doi.org/10.1016/j.critrevonc.2016.02.001 DO - 10.1016/j.critrevonc.2016.02.001 ID - Gandini2016 ER - TY - JOUR AU - Kluger, H. M. AU - Zito, C. R. AU - Turcu, G. AU - Baine, M. K. AU - Zhang, H. AU - Adeniran, A. PY - 2017 DA - 2017// TI - PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-3146 DO - 10.1158/1078-0432.CCR-16-3146 ID - Kluger2017 ER - TY - JOUR AU - Hugo, W. AU - Zaretsky, J. M. AU - Sun, L. AU - Song, C. AU - Moreno, B. H. AU - Hu-Lieskovan, S. PY - 2017 DA - 2017// TI - Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma JO - Cell VL - 168 UR - https://doi.org/10.1016/j.cell.2017.01.010 DO - 10.1016/j.cell.2017.01.010 ID - Hugo2017 ER - TY - JOUR AU - Konishi, J. AU - Yamazaki, K. AU - Azuma, M. AU - Kinoshita, I. AU - Dosaka-Akita, H. AU - Nishimura, M. PY - 2004 DA - 2004// TI - B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-04-0428 DO - 10.1158/1078-0432.CCR-04-0428 ID - Konishi2004 ER - TY - JOUR AU - Madore, J. AU - Vilain, R. E. AU - Menzies, A. M. AU - Kakavand, H. AU - Wilmott, J. S. AU - Hyman, J. PY - 2015 DA - 2015// TI - PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L 1 clinical trials JO - Pigment Cell Melanoma Res VL - 28 UR - https://doi.org/10.1111/pcmr.12340 DO - 10.1111/pcmr.12340 ID - Madore2015 ER - TY - JOUR AU - Dunn, G. P. AU - Bruce, A. T. AU - Ikeda, H. AU - Old, L. J. AU - Schreiber, R. D. PY - 2002 DA - 2002// TI - Cancer immunoediting: from immunosurveillance to tumor escape JO - Nat Immunol VL - 3 UR - https://doi.org/10.1038/ni1102-991 DO - 10.1038/ni1102-991 ID - Dunn2002 ER - TY - JOUR AU - Rizvi, H. AU - Sanchez-Vega, F. AU - La, K. AU - Chatila, W. AU - Jonsson, P. AU - Halpenny, D. PY - 2018 DA - 2018// TI - Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.75.3384 DO - 10.1200/JCO.2017.75.3384 ID - Rizvi2018 ER - TY - JOUR AU - Hellmann, M. D. AU - Ciuleanu, T. -. E. AU - Pluzanski, A. AU - Lee, J. S. AU - Otterson, G. A. AU - Audigier-Valette, C. PY - 2018 DA - 2018// TI - Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1801946 DO - 10.1056/NEJMoa1801946 ID - Hellmann2018 ER - TY - JOUR AU - Snyder, A. AU - Makarov, V. AU - Merghoub, T. AU - Yuan, J. AU - Zaretsky, J. M. AU - Desrichard, A. PY - 2014 DA - 2014// TI - Genetic basis for clinical response to CTLA-4 blockade in melanoma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1406498 DO - 10.1056/NEJMoa1406498 ID - Snyder2014 ER - TY - JOUR AU - Allen, E. M. AU - Miao, D. AU - Schilling, B. AU - Shukla, S. A. AU - Blank, C. AU - Zimmer, L. PY - 2015 DA - 2015// TI - Genomic correlates of response to CTLA-4 blockade in metastatic melanoma JO - Science VL - 350 UR - https://doi.org/10.1126/science.aad0095 DO - 10.1126/science.aad0095 ID - Allen2015 ER - TY - JOUR AU - Eroglu, Z. AU - Zaretsky, J. M. AU - Hu-Lieskovan, S. AU - Kim, D. W. AU - Algazi, A. AU - Johnson, D. B. PY - 2018 DA - 2018// TI - High response rate to PD-1 blockade in desmoplastic melanomas JO - Nature VL - 553 UR - https://doi.org/10.1038/nature25187 DO - 10.1038/nature25187 ID - Eroglu2018 ER - TY - JOUR AU - Ansell, S. M. AU - Lesokhin, A. M. AU - Borrello, I. AU - Halwani, A. AU - Scott, E. C. AU - Gutierrez, M. PY - 2015 DA - 2015// TI - PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1411087 DO - 10.1056/NEJMoa1411087 ID - Ansell2015 ER - TY - JOUR AU - Nghiem, P. T. AU - Bhatia, S. AU - Lipson, E. J. AU - Kudchadkar, R. R. AU - Miller, N. J. AU - Annamalai, L. PY - 2016 DA - 2016// TI - PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma JO - N Engl J Med VL - 374 UR - https://doi.org/10.1056/NEJMoa1603702 DO - 10.1056/NEJMoa1603702 ID - Nghiem2016 ER - TY - JOUR AU - Miao, D. AU - Margolis, C. A. AU - Vokes, N. I. AU - Liu, D. AU - Taylor-Weiner, A. AU - Wankowicz, S. M. PY - 2018 DA - 2018// TI - Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors JO - Nat Genet VL - 50 UR - https://doi.org/10.1038/s41588-018-0200-2 DO - 10.1038/s41588-018-0200-2 ID - Miao2018 ER - TY - JOUR AU - Riaz, N. AU - Morris, L. AU - Havel, J. J. AU - Makarov, V. AU - Desrichard, A. AU - Chan, T. A. PY - 2016 DA - 2016// TI - The role of neoantigens in response to immune checkpoint blockade JO - Int Immunol VL - 28 UR - https://doi.org/10.1093/intimm/dxw019 DO - 10.1093/intimm/dxw019 ID - Riaz2016 ER - TY - JOUR AU - Ott, P. A. AU - Hu, Z. AU - Keskin, D. B. AU - Shukla, S. A. AU - Sun, J. AU - Bozym, D. J. PY - 2017 DA - 2017// TI - An immunogenic personal neoantigen vaccine for patients with melanoma JO - Nature VL - 547 UR - https://doi.org/10.1038/nature22991 DO - 10.1038/nature22991 ID - Ott2017 ER - TY - JOUR AU - Carreno, B. M. AU - Magrini, V. AU - Becker-Hapak, M. AU - Kaabinejadian, S. AU - Hundal, J. AU - Petti, A. A. PY - 2015 DA - 2015// TI - Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa3828 DO - 10.1126/science.aaa3828 ID - Carreno2015 ER - TY - JOUR AU - Kim, H. AU - Jen, J. AU - Vogelstein, B. AU - Hamilton, S. R. PY - 1994 DA - 1994// TI - Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences JO - Am J Pathol VL - 145 ID - Kim1994 ER - TY - JOUR AU - Lengauer, C. AU - Kinzler, K. W. AU - Vogelstein, B. PY - 1998 DA - 1998// TI - Genetic instabilities in human cancers JO - Nature VL - 396 UR - https://doi.org/10.1038/25292 DO - 10.1038/25292 ID - Lengauer1998 ER - TY - JOUR AU - Dolcetti, R. AU - Viel, A. AU - Doglioni, C. AU - Russo, A. AU - Guidoboni, M. AU - Capozzi, E. PY - 1999 DA - 1999// TI - High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability JO - Am J Pathol VL - 154 UR - https://doi.org/10.1016/S0002-9440(10)65436-3 DO - 10.1016/S0002-9440(10)65436-3 ID - Dolcetti1999 ER - TY - JOUR AU - Smyrk, T. C. AU - Watson, P. AU - Kaul, K. AU - Lynch, H. T. PY - 2001 DA - 2001// TI - Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma JO - Cancer VL - 91 UR - https://doi.org/3.0.CO;2-U DO - 3.0.CO;2-U ID - Smyrk2001 ER - TY - JOUR AU - Strickland, K. C. AU - Howitt, B. E. AU - Shukla, S. A. AU - Rodig, S. AU - Ritterhouse, L. L. AU - Liu, J. F. PY - 2016 DA - 2016// TI - Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.7277 DO - 10.18632/oncotarget.7277 ID - Strickland2016 ER - TY - JOUR AU - Teo, M. Y. AU - Seier, K. AU - Ostrovnaya, I. AU - Regazzi, A. M. AU - Kania, B. E. AU - Moran, M. M. PY - 2018 DA - 2018// TI - Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-l1 blockade in advanced urothelial cancers JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.75.7740 DO - 10.1200/JCO.2017.75.7740 ID - Teo2018 ER - TY - JOUR AU - Le, D. T. AU - Durham, J. N. AU - Smith, K. N. AU - Wang, H. AU - Bartlett, B. R. AU - Aulakh, L. K. PY - 2017 DA - 2017// TI - Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade JO - Science VL - 357 UR - https://doi.org/10.1126/science.aan6733 DO - 10.1126/science.aan6733 ID - Le2017 ER - TY - JOUR AU - Alexandrov, L. B. AU - Nik-Zainal, S. AU - Wedge, D. C. AU - Aparicio, S. A. J. R. AU - Behjati, S. AU - Biankin, A. V. PY - 2013 DA - 2013// TI - Signatures of mutational processes in human cancer JO - Nature VL - 500 UR - https://doi.org/10.1038/nature12477 DO - 10.1038/nature12477 ID - Alexandrov2013 ER - TY - JOUR AU - Kim, S. T. AU - Cristescu, R. AU - Bass, A. J. AU - Kim, K. -. M. AU - Odegaard, J. I. AU - Kim, K. PY - 2018 DA - 2018// TI - Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0101-z DO - 10.1038/s41591-018-0101-z ID - Kim2018 ER - TY - JOUR AU - McGranahan, N. AU - Furness, A. J. S. AU - Rosenthal, R. AU - Ramskov, S. AU - Lyngaa, R. AU - Saini, S. K. PY - 2016 DA - 2016// TI - Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade JO - Science VL - 351 UR - https://doi.org/10.1126/science.aaf1490 DO - 10.1126/science.aaf1490 ID - McGranahan2016 ER - TY - JOUR AU - Riaz, N. AU - Havel, J. J. AU - Makarov, V. AU - Desrichard, A. AU - Urba, W. J. AU - Sims, J. S. PY - 2017 DA - 2017// TI - Tumor and microenvironment evolution during immunotherapy with nivolumab JO - Cell VL - 171 UR - https://doi.org/10.1016/j.cell.2017.09.028 DO - 10.1016/j.cell.2017.09.028 ID - Riaz2017 ER - TY - JOUR AU - Dhillon, A. S. AU - Hagan, S. AU - Rath, O. AU - Kolch, W. PY - 2007 DA - 2007// TI - MAP kinase signalling pathways in cancer JO - Oncogene VL - 26 UR - https://doi.org/10.1038/sj.onc.1210421 DO - 10.1038/sj.onc.1210421 ID - Dhillon2007 ER - TY - JOUR AU - Loi, S. AU - Dushyanthen, S. AU - Beavis, P. A. AU - Salgado, R. AU - Denkert, C. AU - Savas, P. PY - 2016 DA - 2016// TI - RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1125 DO - 10.1158/1078-0432.CCR-15-1125 ID - Loi2016 ER - TY - JOUR AU - Hu-Lieskovan, S. AU - Mok, S. AU - Homet Moreno, B. AU - Tsoi, J. AU - Robert, L. AU - Goedert, L. PY - 2015 DA - 2015// TI - Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma JO - Sci Transl Med VL - 7 UR - https://doi.org/10.1126/scitranslmed.aaa4691 DO - 10.1126/scitranslmed.aaa4691 ID - Hu-Lieskovan2015 ER - TY - JOUR AU - Liu, L. AU - Mayes, P. A. AU - Eastman, S. AU - Shi, H. AU - Yadavilli, S. AU - Zhang, T. PY - 2015 DA - 2015// TI - The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4 JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2339 DO - 10.1158/1078-0432.CCR-14-2339 ID - Liu2015 ER - TY - JOUR AU - D’Souza, W. N. AU - Chang, C. -. F. AU - Fischer, A. M. AU - Li, M. AU - Hedrick, S. M. PY - 2008 DA - 2008// TI - The Erk2 MAPK regulates CD8 T cell proliferation and survival JO - J Immunol VL - 181 UR - https://doi.org/10.4049/jimmunol.181.11.7617 DO - 10.4049/jimmunol.181.11.7617 ID - D’Souza2008 ER - TY - JOUR AU - Ebert, P. J. R. AU - Cheung, J. AU - Yang, Y. AU - McNamara, E. AU - Hong, R. AU - Moskalenko, M. PY - 2016 DA - 2016// TI - MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade JO - Immunity VL - 44 UR - https://doi.org/10.1016/j.immuni.2016.01.024 DO - 10.1016/j.immuni.2016.01.024 ID - Ebert2016 ER - TY - JOUR AU - Dushyanthen, S. AU - Teo, Z. L. AU - Caramia, F. AU - Savas, P. AU - Mintoff, C. P. AU - Virassamy, B. PY - 2017 DA - 2017// TI - Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer JO - Nat Commun VL - 8 UR - https://doi.org/10.1038/s41467-017-00728-9 DO - 10.1038/s41467-017-00728-9 ID - Dushyanthen2017 ER - TY - JOUR AU - Skoulidis, F. AU - Byers, L. A. AU - Diao, L. AU - Papadimitrakopoulou, V. A. AU - Tong, P. AU - Izzo, J. PY - 2015 DA - 2015// TI - Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities JO - Cancer Discov. VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-14-1236 DO - 10.1158/2159-8290.CD-14-1236 ID - Skoulidis2015 ER - TY - JOUR AU - Skoulidis, F. AU - Goldberg, M. E. AU - Greenawalt, D. M. AU - Hellmann, M. D. AU - Awad, M. M. AU - Gainor, J. F. PY - 2018 DA - 2018// TI - Mutations and PD-1 inhibitor resistance in mutant lung adenocarcinoma JO - Cancer Discov. VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-18-0099 DO - 10.1158/2159-8290.CD-18-0099 ID - Skoulidis2018 ER - TY - JOUR AU - Maehama, T. AU - Dixon, J. E. PY - 1998 DA - 1998// TI - The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate JO - J Biol Chem VL - 273 UR - https://doi.org/10.1074/jbc.273.22.13375 DO - 10.1074/jbc.273.22.13375 ID - Maehama1998 ER - TY - JOUR AU - Liu, P. AU - Cheng, H. AU - Roberts, T. M. AU - Zhao, J. J. PY - 2009 DA - 2009// TI - Targeting the phosphoinositide 3-kinase pathway in cancer JO - Nat Rev Drug Discov VL - 8 UR - https://doi.org/10.1038/nrd2926 DO - 10.1038/nrd2926 ID - Liu2009 ER - TY - JOUR AU - Keniry, M. AU - Parsons, R. PY - 2008 DA - 2008// TI - The role of PTEN signaling perturbations in cancer and in targeted therapy JO - Oncogene VL - 27 UR - https://doi.org/10.1038/onc.2008.248 DO - 10.1038/onc.2008.248 ID - Keniry2008 ER - TY - JOUR AU - Toso, A. AU - Revandkar, A. AU - Mitri, D. AU - Guccini, I. AU - Proietti, M. AU - Sarti, M. PY - 2014 DA - 2014// TI - Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity JO - Cell Rep VL - 9 UR - https://doi.org/10.1016/j.celrep.2014.08.044 DO - 10.1016/j.celrep.2014.08.044 ID - Toso2014 ER - TY - JOUR AU - Peng, W. AU - Chen, J. Q. AU - Liu, C. AU - Malu, S. AU - Creasy, C. AU - Tetzlaff, M. T. PY - 2016 DA - 2016// TI - Loss of PTEN promotes resistance to T cell-mediated immunotherapy JO - Cancer Discov. VL - 6 UR - https://doi.org/10.1158/2159-8290.CD-15-0283 DO - 10.1158/2159-8290.CD-15-0283 ID - Peng2016 ER - TY - JOUR AU - George, S. AU - Miao, D. AU - Demetri, G. D. AU - Adeegbe, D. AU - Rodig, S. J. AU - Shukla, S. PY - 2017 DA - 2017// TI - Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma JO - Immunity VL - 46 UR - https://doi.org/10.1016/j.immuni.2017.02.001 DO - 10.1016/j.immuni.2017.02.001 ID - George2017 ER - TY - JOUR AU - Millis, S. Z. AU - Ikeda, S. AU - Reddy, S. AU - Gatalica, Z. AU - Kurzrock, R. PY - 2016 DA - 2016// TI - Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors JO - JAMA Oncol. VL - 2 UR - https://doi.org/10.1001/jamaoncol.2016.0891 DO - 10.1001/jamaoncol.2016.0891 ID - Millis2016 ER - TY - JOUR AU - Kahn, M. PY - 2014 DA - 2014// TI - Can we safely target the WNT pathway? JO - Nat Rev Drug Discov VL - 13 UR - https://doi.org/10.1038/nrd4233 DO - 10.1038/nrd4233 ID - Kahn2014 ER - TY - JOUR AU - Anastas, J. N. AU - Moon, R. T. PY - 2013 DA - 2013// TI - WNT signalling pathways as therapeutic targets in cancer JO - Nat Rev Cancer VL - 13 UR - https://doi.org/10.1038/nrc3419 DO - 10.1038/nrc3419 ID - Anastas2013 ER - TY - JOUR AU - Zhan, T. AU - Rindtorff, N. AU - Boutros, M. PY - 2017 DA - 2017// TI - Wnt signaling in cancer JO - Oncogene VL - 36 UR - https://doi.org/10.1038/onc.2016.304 DO - 10.1038/onc.2016.304 ID - Zhan2017 ER - TY - JOUR AU - Pai, S. G. AU - Carneiro, B. A. AU - Mota, J. M. AU - Costa, R. AU - Leite, C. A. AU - Barroso-Sousa, R. PY - 2017 DA - 2017// TI - Wnt/beta-catenin pathway: modulating anticancer immune response JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0471-6 DO - 10.1186/s13045-017-0471-6 ID - Pai2017 ER - TY - JOUR AU - Spranger, S. AU - Bao, R. AU - Gajewski, T. F. PY - 2015 DA - 2015// TI - Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity JO - Nature VL - 523 UR - https://doi.org/10.1038/nature14404 DO - 10.1038/nature14404 ID - Spranger2015 ER - TY - JOUR AU - Xiao, Q. AU - Wu, J. AU - Wang, W. -. J. AU - Chen, S. AU - Zheng, Y. AU - Yu, X. PY - 2018 DA - 2018// TI - DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation JO - Nat Med VL - 24 UR - https://doi.org/10.1038/nm.4496 DO - 10.1038/nm.4496 ID - Xiao2018 ER - TY - JOUR AU - Munn, D. H. AU - Mellor, A. L. PY - 2016 DA - 2016// TI - IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance JO - Trends Immunol VL - 37 UR - https://doi.org/10.1016/j.it.2016.01.002 DO - 10.1016/j.it.2016.01.002 ID - Munn2016 ER - TY - JOUR AU - Li, F. AU - Zhang, R. AU - Li, S. AU - Liu, J. PY - 2017 DA - 2017// TI - IDO1: an important immunotherapy target in cancer treatment JO - Int Immunopharmacol VL - 47 UR - https://doi.org/10.1016/j.intimp.2017.03.024 DO - 10.1016/j.intimp.2017.03.024 ID - Li2017 ER - TY - JOUR AU - Toulmonde, M. AU - Penel, N. AU - Adam, J. AU - Chevreau, C. AU - Blay, J. -. Y. AU - Cesne, A. PY - 2018 DA - 2018// TI - Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial JO - JAMA Oncol. VL - 4 UR - https://doi.org/10.1001/jamaoncol.2017.1617 DO - 10.1001/jamaoncol.2017.1617 ID - Toulmonde2018 ER - TY - JOUR AU - Zaretsky, J. M. AU - Garcia-Diaz, A. AU - Shin, D. S. AU - Escuin-Ordinas, H. AU - Hugo, W. AU - Hu-Lieskovan, S. PY - 2016 DA - 2016// TI - Mutations associated with acquired resistance to PD-1 blockade in melanoma JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1604958 DO - 10.1056/NEJMoa1604958 ID - Zaretsky2016 ER - TY - JOUR AU - Tran, E. AU - Robbins, P. F. AU - Lu, Y. -. C. AU - Prickett, T. D. AU - Gartner, J. J. AU - Jia, L. PY - 2016 DA - 2016// TI - T-cell transfer therapy targeting mutant KRAS in cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1609279 DO - 10.1056/NEJMoa1609279 ID - Tran2016 ER - TY - JOUR AU - McGranahan, N. AU - Rosenthal, R. AU - Hiley, C. T. AU - Rowan, A. J. AU - Watkins, T. B. K. AU - Wilson, G. A. PY - 2017 DA - 2017// TI - Allele-specific HLA loss and immune escape in lung cancer evolution JO - Cell VL - 171 UR - https://doi.org/10.1016/j.cell.2017.10.001 DO - 10.1016/j.cell.2017.10.001 ID - McGranahan2017 ER - TY - JOUR AU - Chowell, D. AU - Morris, L. G. T. AU - Grigg, C. M. AU - Weber, J. K. AU - Samstein, R. M. AU - Makarov, V. PY - 2018 DA - 2018// TI - Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy JO - Science VL - 359 UR - https://doi.org/10.1126/science.aao4572 DO - 10.1126/science.aao4572 ID - Chowell2018 ER - TY - JOUR AU - Johnson, D. B. AU - Estrada, M. V. AU - Salgado, R. AU - Sanchez, V. AU - Doxie, D. B. AU - Opalenik, S. R. PY - 2016 DA - 2016// TI - Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms10582 DO - 10.1038/ncomms10582 ID - Johnson2016 ER - TY - JOUR AU - Roemer, M. G. M. AU - Redd, R. A. AU - Cader, F. Z. AU - Pak, C. J. AU - Abdelrahman, S. AU - Ouyang, J. PY - 2018 DA - 2018// TI - Major histocompatibility complex class ii and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.77.3994 DO - 10.1200/JCO.2017.77.3994 ID - Roemer2018 ER - TY - JOUR AU - Rodig, S. c. o. t. t. J. AU - Gusenleitner, D. a. n. i. e. l. AU - Jackson, D. o. n. a. l. d. G. AU - Gjini, E. v. i. s. a. AU - Giobbie-Hurder, A. n. i. t. a. AU - Jin, C. h. e. l. s. e. a. AU - Chang, H. a. n. AU - Lovitch, S. c. o. t. t. B. AU - Horak, C. h. r. i. s. t. i. n. e. AU - Weber, J. e. f. f. r. e. y. S. AU - Weirather, J. a. s. o. n. L. AU - Wolchok, J. e. d. d. D. AU - Postow, M. i. c. h. a. e. l. A. AU - Pavlick, A. n. n. a. C. AU - Chesney, J. a. s. o. n. AU - Hodi, F. S. t. e. p. h. e. n. PY - 2018 DA - 2018// TI - MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma JO - Science Translational Medicine VL - 10 UR - https://doi.org/10.1126/scitranslmed.aar3342 DO - 10.1126/scitranslmed.aar3342 ID - Rodig2018 ER - TY - JOUR AU - Garcia-Diaz, A. AU - Shin, D. S. AU - Moreno, B. H. AU - Saco, J. AU - Escuin-Ordinas, H. AU - Rodriguez, G. A. PY - 2017 DA - 2017// TI - Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression JO - Cell Rep VL - 19 UR - https://doi.org/10.1016/j.celrep.2017.04.031 DO - 10.1016/j.celrep.2017.04.031 ID - Garcia-Diaz2017 ER - TY - JOUR AU - Boehm, U. AU - Klamp, T. AU - Groot, M. AU - Howard, J. C. PY - 1997 DA - 1997// TI - Cellular responses to interferon-γ JO - Annu Rev Immunol VL - 15 UR - https://doi.org/10.1146/annurev.immunol.15.1.749 DO - 10.1146/annurev.immunol.15.1.749 ID - Boehm1997 ER - TY - JOUR AU - Moon, J. W. AU - Kong, S. -. K. AU - Kim, B. S. AU - Kim, H. J. AU - Lim, H. AU - Noh, K. PY - 2017 DA - 2017// TI - IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/s41598-017-18132-0 DO - 10.1038/s41598-017-18132-0 ID - Moon2017 ER - TY - JOUR AU - Mimura, K. AU - Teh, J. L. AU - Okayama, H. AU - Shiraishi, K. AU - Kua, L. -. F. AU - Koh, V. PY - 2018 DA - 2018// TI - PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer JO - Cancer Sci VL - 109 UR - https://doi.org/10.1111/cas.13424 DO - 10.1111/cas.13424 ID - Mimura2018 ER - TY - JOUR AU - Abiko, K. AU - Matsumura, N. AU - Hamanishi, J. AU - Horikawa, N. AU - Murakami, R. AU - Yamaguchi, K. PY - 2015 DA - 2015// TI - IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer JO - Br J Cancer VL - 112 UR - https://doi.org/10.1038/bjc.2015.101 DO - 10.1038/bjc.2015.101 ID - Abiko2015 ER - TY - JOUR AU - Goodman, A. M. AU - Piccioni, D. AU - Kato, S. AU - Boichard, A. AU - Wang, H. -. Y. AU - Frampton, G. PY - 2018 DA - 2018// TI - Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors JO - JAMA Oncol. VL - 4 UR - https://doi.org/10.1001/jamaoncol.2018.1701 DO - 10.1001/jamaoncol.2018.1701 ID - Goodman2018 ER - TY - JOUR AU - Manguso, R. T. AU - Pope, H. W. AU - Zimmer, M. D. AU - Brown, F. D. AU - Yates, K. B. AU - Miller, B. C. PY - 2017 DA - 2017// TI - In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target JO - Nature VL - 547 UR - https://doi.org/10.1038/nature23270 DO - 10.1038/nature23270 ID - Manguso2017 ER - TY - JOUR AU - Shin, D. S. AU - Zaretsky, J. M. AU - Escuin-Ordinas, H. AU - Garcia-Diaz, A. AU - Hu-Lieskovan, S. AU - Kalbasi, A. PY - 2017 DA - 2017// TI - Primary resistance to PD-1 blockade mediated by JAK1/2 mutations JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-16-1223 DO - 10.1158/2159-8290.CD-16-1223 ID - Shin2017 ER - TY - JOUR AU - Gao, J. AU - Shi, L. Z. AU - Zhao, H. AU - Chen, J. AU - Xiong, L. AU - He, Q. PY - 2016 DA - 2016// TI - Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy JO - Cell VL - 167 UR - https://doi.org/10.1016/j.cell.2016.08.069 DO - 10.1016/j.cell.2016.08.069 ID - Gao2016 ER - TY - JOUR AU - Allen, E. M. AU - Golay, H. G. AU - Liu, Y. AU - Koyama, S. AU - Wong, K. AU - Taylor-Weiner, A. PY - 2015 DA - 2015// TI - Long-term benefit of PD-L1 blockade in lung cancer associated with JAK3 activation JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-15-0024 DO - 10.1158/2326-6066.CIR-15-0024 ID - Allen2015 ER - TY - JOUR AU - Patel, S. J. AU - Sanjana, N. E. AU - Kishton, R. J. AU - Eidizadeh, A. AU - Vodnala, S. K. AU - Cam, M. PY - 2017 DA - 2017// TI - Identification of essential genes for cancer immunotherapy JO - Nature VL - 548 UR - https://doi.org/10.1038/nature23477 DO - 10.1038/nature23477 ID - Patel2017 ER - TY - JOUR AU - Luo, N. AU - Formisano, L. AU - Gonzalez-Ericsson, P. I. AU - Sanchez, V. AU - Dean, P. T. AU - Opalenik, S. R. PY - 2018 DA - 2018// TI - Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2 JO - Oncoimmunology. VL - 7 UR - https://doi.org/10.1080/2162402X.2018.1438106 DO - 10.1080/2162402X.2018.1438106 ID - Luo2018 ER - TY - STD TI - Najafi M, Farhood B, Mortezaee K. Contribution of regulatory T cells to cancer: a review. J Cell Physiol. 2018. https://doi.org/10.1002/jcp.27553. ID - ref95 ER - TY - JOUR AU - Tauriello, D. V. F. AU - Palomo-Ponce, S. AU - Stork, D. AU - Berenguer-Llergo, A. AU - Badia-Ramentol, J. AU - Iglesias, M. PY - 2018 DA - 2018// TI - TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis JO - Nature VL - 554 UR - https://doi.org/10.1038/nature25492 DO - 10.1038/nature25492 ID - Tauriello2018 ER - TY - JOUR AU - Mariathasan, S. AU - Turley, S. J. AU - Nickles, D. AU - Castiglioni, A. AU - Yuen, K. AU - Wang, Y. PY - 2018 DA - 2018// TI - TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells JO - Nature VL - 554 UR - https://doi.org/10.1038/nature25501 DO - 10.1038/nature25501 ID - Mariathasan2018 ER - TY - JOUR AU - Shain, A. H. AU - Pollack, J. R. PY - 2013 DA - 2013// TI - The spectrum of SWI/SNF mutations, ubiquitous in human cancers JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0055119 DO - 10.1371/journal.pone.0055119 ID - Shain2013 ER - TY - JOUR AU - Kadoch, C. AU - Hargreaves, D. C. AU - Hodges, C. AU - Elias, L. AU - Ho, L. AU - Ranish, J. PY - 2013 DA - 2013// TI - Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy JO - Nat Genet VL - 45 UR - https://doi.org/10.1038/ng.2628 DO - 10.1038/ng.2628 ID - Kadoch2013 ER - TY - JOUR AU - Wang, X. AU - Haswell, J. R. AU - Roberts, C. W. M. PY - 2014 DA - 2014// TI - Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-0280 DO - 10.1158/1078-0432.CCR-13-0280 ID - Wang2014 ER - TY - JOUR AU - Miao, D. AU - Margolis, C. A. AU - Gao, W. AU - Voss, M. H. AU - Li, W. AU - Martini, D. J. PY - 2018 DA - 2018// TI - Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma JO - Science VL - 359 UR - https://doi.org/10.1126/science.aan5951 DO - 10.1126/science.aan5951 ID - Miao2018 ER - TY - JOUR AU - Pan, D. AU - Kobayashi, A. AU - Jiang, P. AU - Ferrari de Andrade, L. AU - Tay, R. E. AU - Luoma, A. M. PY - 2018 DA - 2018// TI - A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing JO - Science VL - 359 UR - https://doi.org/10.1126/science.aao1710 DO - 10.1126/science.aao1710 ID - Pan2018 ER - TY - JOUR AU - Zingg, D. AU - Arenas-Ramirez, N. AU - Sahin, D. AU - Rosalia, R. A. AU - Antunes, A. T. AU - Haeusel, J. PY - 2017 DA - 2017// TI - The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy JO - Cell Rep VL - 20 UR - https://doi.org/10.1016/j.celrep.2017.07.007 DO - 10.1016/j.celrep.2017.07.007 ID - Zingg2017 ER - TY - JOUR AU - Shu, X. -. S. AU - Zhao, Y. AU - Sun, Y. AU - Zhong, L. AU - Cheng, Y. AU - Zhang, Y. PY - 2018 DA - 2018// TI - The epigenetic modifier PBRM1 restricts the basal activity of the innate immune system by repressing retinoic acid-inducible gene-I-like receptor signalling and is a potential prognostic biomarker for colon cancer JO - J Pathol VL - 244 UR - https://doi.org/10.1002/path.4986 DO - 10.1002/path.4986 ID - Shu2018 ER - TY - JOUR AU - Abou El Hassan, M. AU - Huang, K. AU - MBK, E. AU - Zhao, M. AU - Song, L. AU - Yu, T. PY - 2015 DA - 2015// TI - Cancer cells hijack PRC2 to modify multiple cytokine pathways JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0126466 DO - 10.1371/journal.pone.0126466 ID - Abou El Hassan2015 ER - TY - JOUR AU - Jelinic, P. AU - Ricca, J. AU - Oudenhove, E. AU - Olvera, N. AU - Merghoub, T. AU - Levine, D. A. PY - 2018 DA - 2018// TI - Immune-active microenvironment in small cell carcinoma of the ovary, hypercalcemic type: rationale for immune checkpoint blockade JO - J Natl Cancer Inst VL - 110 UR - https://doi.org/10.1093/jnci/djx277 DO - 10.1093/jnci/djx277 ID - Jelinic2018 ER - TY - JOUR AU - Shen, J. AU - Ju, Z. AU - Zhao, W. AU - Wang, L. AU - Peng, Y. AU - Ge, Z. PY - 2018 DA - 2018// TI - ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0012-z DO - 10.1038/s41591-018-0012-z ID - Shen2018 ER - TY - JOUR AU - Strick, R. AU - Strissel, P. L. AU - Baylin, S. B. AU - Chiappinelli, K. B. PY - 2016 DA - 2016// TI - Unraveling the molecular pathways of DNA-methylation inhibitors: human endogenous retroviruses induce the innate immune response in tumors JO - Oncoimmunology. VL - 5 UR - https://doi.org/10.1080/2162402X.2015.1122160 DO - 10.1080/2162402X.2015.1122160 ID - Strick2016 ER - TY - JOUR AU - Chiappinelli, K. B. AU - Strissel, P. L. AU - Desrichard, A. AU - Li, H. AU - Henke, C. AU - Akman, B. PY - 2017 DA - 2017// TI - Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses JO - Cell VL - 169 UR - https://doi.org/10.1016/j.cell.2017.03.036 DO - 10.1016/j.cell.2017.03.036 ID - Chiappinelli2017 ER - TY - JOUR AU - Cañadas, I. AU - Thummalapalli, R. AU - Kim, J. W. AU - Kitajima, S. AU - Jenkins, R. W. AU - Christensen, C. L. PY - 2018 DA - 2018// TI - Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0116-5 DO - 10.1038/s41591-018-0116-5 ID - Cañadas2018 ER - TY - JOUR AU - Sheng, W. AU - LaFleur, M. W. AU - Nguyen, T. H. AU - Chen, S. AU - Chakravarthy, A. AU - Conway, J. R. PY - 2018 DA - 2018// TI - LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade JO - Cell VL - 174 UR - https://doi.org/10.1016/j.cell.2018.05.052 DO - 10.1016/j.cell.2018.05.052 ID - Sheng2018 ER - TY - JOUR AU - Chaerkady, R. AU - Harsha, H. C. AU - Nalli, A. AU - Gucek, M. AU - Vivekanandan, P. AU - Akhtar, J. PY - 2008 DA - 2008// TI - A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma JO - J Proteome Res VL - 7 UR - https://doi.org/10.1021/pr800197z DO - 10.1021/pr800197z ID - Chaerkady2008 ER - TY - JOUR AU - Lee, J. S. AU - Adler, L. AU - Karathia, H. AU - Carmel, N. AU - Rabinovich, S. AU - Auslander, N. PY - 2018 DA - 2018// TI - Urea cycle dysregulation generates clinically relevant genomic and biochemical signatures JO - Cell VL - 174 UR - https://doi.org/10.1016/j.cell.2018.07.019 DO - 10.1016/j.cell.2018.07.019 ID - Lee2018 ER - TY - JOUR AU - Syed, N. AU - Langer, J. AU - Janczar, K. AU - Singh, P. AU - Lo Nigro, C. AU - Lattanzio, L. PY - 2013 DA - 2013// TI - Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma JO - Cell Death Dis VL - 4 UR - https://doi.org/10.1038/cddis.2012.197 DO - 10.1038/cddis.2012.197 ID - Syed2013 ER - TY - JOUR AU - Gopalakrishnan, V. AU - Wargo, J. A. PY - 2017 DA - 2017// TI - Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients JO - Science VL - 4236 ID - Gopalakrishnan2017 ER - TY - JOUR AU - Routy, B. AU - Chatelier, E. AU - Derosa, L. AU - Duong, C. P. M. AU - Alou, M. T. AU - Daillère, R. PY - 2018 DA - 2018// TI - Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors JO - Science VL - 359 UR - https://doi.org/10.1126/science.aan3706 DO - 10.1126/science.aan3706 ID - Routy2018 ER - TY - JOUR AU - Matson, V. AU - Fessler, J. AU - Bao, R. AU - Chongsuwat, T. AU - Zha, Y. AU - Alegre, M. -. L. PY - 2018 DA - 2018// TI - The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients JO - Science VL - 359 UR - https://doi.org/10.1126/science.aao3290 DO - 10.1126/science.aao3290 ID - Matson2018 ER - TY - JOUR AU - Garon, E. B. AU - Rizvi, N. A. AU - Hui, R. AU - Leighl, N. AU - Balmanoukian, A. S. AU - Eder, J. P. PY - 2015 DA - 2015// TI - Pembrolizumab for the treatment of non–small-cell lung cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1501824 DO - 10.1056/NEJMoa1501824 ID - Garon2015 ER - TY - JOUR AU - Eisenstein, M. PY - 2017 DA - 2017// TI - Making cancer immunotherapy a surer bet JO - Nature VL - 552 UR - https://doi.org/10.1038/d41586-017-08704-5 DO - 10.1038/d41586-017-08704-5 ID - Eisenstein2017 ER - TY - STD TI - US Food & Drug Administration. FDA alerts health care professionals and oncology clinical investigators about an efficacy issue identified in clinical trials for some patients taking keytruda (pembrolizumab) or tecentriq (atezolizumab) as monotherapy to treat urothelial cancer with low expression of PD-L1. https://www.fda.gov/Drugs/DrugSafety/ucm608075. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/DrugSafety/ucm608075 ID - ref120 ER - TY - JOUR AU - Ayers, M. AU - Lunceford, J. AU - Nebozhyn, M. AU - Murphy, E. AU - Loboda, A. AU - Kaufman, D. R. PY - 2017 DA - 2017// TI - IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade JO - J Clin Invest VL - 127 UR - https://doi.org/10.1172/JCI91190 DO - 10.1172/JCI91190 ID - Ayers2017 ER - TY - JOUR AU - Jiang, P. AU - Gu, S. AU - Pan, D. AU - Fu, J. AU - Sahu, A. AU - Hu, X. PY - 2018 DA - 2018// TI - Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0136-1 DO - 10.1038/s41591-018-0136-1 ID - Jiang2018 ER - TY - JOUR AU - Cristescu, R. a. z. v. a. n. AU - Mogg, R. o. b. i. n. AU - Ayers, M. a. r. k. AU - Albright, A. n. d. r. e. w. AU - Murphy, E. r. i. n. AU - Yearley, J. e. n. n. i. f. e. r. AU - Sher, X. i. n. w. e. i. AU - Liu, X. i. a. o. Q. i. a. o. AU - Lu, H. o. n. g. c. h. a. o. AU - Nebozhyn, M. i. c. h. a. e. l. AU - Zhang, C. h. u. n. s. h. e. n. g. AU - Lunceford, J. a. r. e. d. K. AU - Joe, A. n. d. r. e. w. AU - Cheng, J. o. n. a. t. h. a. n. AU - Webber, A. n. d. r. e. a. L. AU - Ibrahim, N. a. g. e. a. t. t. e. AU - Plimack, E. l. i. z. a. b. e. t. h. R. AU - Ott, P. a. t. r. i. c. k. A. AU - Seiwert, T. a. n. g. u. y. Y. AU - Ribas, A. n. t. o. n. i. AU - McClanahan, T. e. r. r. i. l. l. K. AU - Tomassini, J. o. a. n. n. e. E. AU - Loboda, A. n. d. r. e. y. AU - Kaufman, D. a. v. i. d. PY - 2018 DA - 2018// TI - Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy JO - Science VL - 362 UR - https://doi.org/10.1126/science.aar3593 DO - 10.1126/science.aar3593 ID - Cristescu2018 ER - TY - JOUR AU - Gandara, D. R. AU - Paul, S. M. AU - Kowanetz, M. AU - Schleifman, E. AU - Zou, W. AU - Li, Y. PY - 2018 DA - 2018// TI - Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0134-3 DO - 10.1038/s41591-018-0134-3 ID - Gandara2018 ER - TY - JOUR AU - Lee, J. H. AU - Long, G. V. AU - Menzies, A. M. AU - Lo, S. AU - Guminski, A. AU - Whitbourne, K. PY - 2018 DA - 2018// TI - Association between circulating tumor dna and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies JO - JAMA Oncol VL - 4 UR - https://doi.org/10.1001/jamaoncol.2017.5332 DO - 10.1001/jamaoncol.2017.5332 ID - Lee2018 ER - TY - JOUR AU - Chen, G. AU - Huang, A. C. AU - Zhang, W. AU - Zhang, G. AU - Wu, M. AU - Xu, W. PY - 2018 DA - 2018// TI - Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response JO - Nature VL - 560 UR - https://doi.org/10.1038/s41586-018-0392-8 DO - 10.1038/s41586-018-0392-8 ID - Chen2018 ER - TY - JOUR AU - Gandhi, L. AU - Rodríguez-Abreu, D. AU - Gadgeel, S. AU - Esteban, E. AU - Felip, E. AU - Angelis, F. PY - 2018 DA - 2018// TI - Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1801005 DO - 10.1056/NEJMoa1801005 ID - Gandhi2018 ER - TY - JOUR AU - Motzer, R. J. AU - Tannir, N. M. AU - McDermott, D. F. AU - Arén Frontera, O. AU - Melichar, B. AU - Choueiri, T. K. PY - 2018 DA - 2018// TI - Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1712126 DO - 10.1056/NEJMoa1712126 ID - Motzer2018 ER - TY - STD TI - Andre T, Lonardi S, Wong M, Lenz H-J, Gelsomino F, Aglietta M, et al. Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): first report of the full cohort from CheckMate-142. J Clin Oncol. 2018. https://doi.org/10.1200/JCO.2018.36.4_suppl.553. ID - ref129 ER - TY - JOUR AU - Hellmann, M. D. AU - Nathanson, T. AU - Rizvi, H. AU - Creelan, B. C. AU - Sanchez-Vega, F. AU - Ahuja, A. PY - 2018 DA - 2018// TI - Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer JO - Cancer Cell VL - 33 UR - https://doi.org/10.1016/j.ccell.2018.03.018 DO - 10.1016/j.ccell.2018.03.018 ID - Hellmann2018 ER - TY - JOUR AU - Hellmann, M. D. AU - Callahan, M. K. AU - Awad, M. M. AU - Calvo, E. AU - Ascierto, P. A. AU - Atmaca, A. PY - 2018 DA - 2018// TI - Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer JO - Cancer Cell VL - 33 UR - https://doi.org/10.1016/j.ccell.2018.04.001 DO - 10.1016/j.ccell.2018.04.001 ID - Hellmann2018 ER - TY - JOUR AU - Sanlorenzo, M. AU - Vujic, I. AU - Floris, A. AU - Novelli, M. AU - Gammaitoni, L. AU - Giraudo, L. PY - 2018 DA - 2018// TI - BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-1914 DO - 10.1158/1078-0432.CCR-17-1914 ID - Sanlorenzo2018 ER - TY - JOUR AU - Donia, M. AU - Fagone, P. AU - Nicoletti, F. AU - Andersen, R. S. AU - Høgdall, E. AU - Straten, P. T. PY - 2012 DA - 2012// TI - BRAF inhibition improves tumor recognition by the immune system: potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer JO - Oncoimmunology VL - 1 UR - https://doi.org/10.4161/onci.21940 DO - 10.4161/onci.21940 ID - Donia2012 ER - TY - JOUR AU - Cooper, Z. A. AU - Frederick, D. T. AU - Ahmed, Z. AU - Wargo, J. A. PY - 2013 DA - 2013// TI - Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma JO - Oncoimmunology. VL - 2 UR - https://doi.org/10.4161/onci.24320 DO - 10.4161/onci.24320 ID - Cooper2013 ER - TY - JOUR AU - Frederick, D. T. AU - Piris, A. AU - Cogdill, A. P. AU - Cooper, Z. A. AU - Lezcano, C. AU - Ferrone, C. R. PY - 2013 DA - 2013// TI - BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-1630 DO - 10.1158/1078-0432.CCR-12-1630 ID - Frederick2013 ER - TY - JOUR AU - Li, B. AU - Lalani, A. S. AU - Harding, T. C. AU - Luan, B. AU - Koprivnikar, K. AU - Tu, G. H. PY - 2006 DA - 2006// TI - Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF–secreting cancer immunotherapy JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-1558 DO - 10.1158/1078-0432.CCR-06-1558 ID - Li2006 ER - TY - JOUR AU - Einstein, D. J. AU - McDermott, D. F. PY - 2017 DA - 2017// TI - Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer JO - Clin Adv Hematol Oncol VL - 15 ID - Einstein2017 ER - TY - JOUR AU - Long, G. e. o. r. g. i. n. a. V. AU - Dummer, R. e. i. n. h. a. r. d. AU - Hamid, O. m. i. d. AU - Gajewski, T. h. o. m. a. s. AU - Caglevic, C. h. r. i. s. t. i. a. n. AU - Dalle, S. t. é. p. h. a. n. e. AU - Arance, A. n. a. AU - Carlino, M. a. t. t. e. o. S. AU - Grob, J. e. a. n. -. J. a. c. q. u. e. s. AU - Kim, T. a. e. M. i. n. AU - Demidov, L. e. v. V. AU - Robert, C. a. r. o. l. i. n. e. AU - Larkin, J. a. m. e. s. M. G. AU - Anderson, J. a. m. e. s. AU - Maleski, J. a. n. e. t. E. AU - Jones, M. a. r. k. M. AU - Diede, S. c. o. t. t. J. AU - Mitchell, T. a. r. a. C. PY - 2018 DA - 2018// TI - Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study JO - Journal of Clinical Oncology VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.108 DO - 10.1200/JCO.2018.36.15_suppl.108 ID - Long2018 ER - TY - JOUR AU - Bendell, J. AU - Ciardiello, F. AU - Tabernero, J. AU - Tebbutt, N. AU - Eng, C. AU - Bartolomeo, M. PY - 2018 DA - 2018// TI - Efficacy and safety results from IMblaze370, a randomised phase III study comparing atezolizumab plus cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdy208.003 DO - 10.1093/annonc/mdy208.003 ID - Bendell2018 ER - TY - JOUR AU - Ribas, A. AU - Hodi, F. S. AU - Callahan, M. AU - Konto, C. AU - Wolchok, J. PY - 2013 DA - 2013// TI - Hepatotoxicity with combination of vemurafenib and ipilimumab JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMc1302338 DO - 10.1056/NEJMc1302338 ID - Ribas2013 ER - TY - JOUR AU - Mazzone, R. AU - Zwergel, C. AU - Mai, A. AU - Valente, S. PY - 2017 DA - 2017// TI - Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy JO - Clin Epigenet VL - 9 UR - https://doi.org/10.1186/s13148-017-0358-y DO - 10.1186/s13148-017-0358-y ID - Mazzone2017 ER - TY - JOUR AU - Li, H. AU - Chiappinelli, K. B. AU - Guzzetta, A. A. AU - Easwaran, H. AU - Yen, R. -. W. C. AU - Vatapalli, R. PY - 2014 DA - 2014// TI - Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers JO - Oncotarget VL - 5 UR - https://doi.org/10.18632/oncotarget.1782 DO - 10.18632/oncotarget.1782 ID - Li2014 ER - TY - JOUR AU - Postow, M. A. AU - Callahan, M. K. AU - Barker, C. A. AU - Yamada, Y. AU - Yuan, J. AU - Kitano, S. PY - 2012 DA - 2012// TI - Immunologic correlates of the abscopal effect in a patient with melanoma JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1112824 DO - 10.1056/NEJMoa1112824 ID - Postow2012 ER - TY - STD TI - Formenti SC, Rudqvist N-P, Golden E, Cooper B, Wennerberg E, Lhuillier C, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018. doi.org/10.1038/s41591-018-0232-2. UR - http://doi.org/10.1038/s41591-018-0232-2 ID - ref144 ER - TY - JOUR AU - Ko, E. C. AU - Formenti, S. C. PY - 2018 DA - 2018// TI - Radiotherapy and checkpoint inhibitors: a winning new combination? JO - Ther Adv Med Oncol VL - 10 UR - https://doi.org/10.1177/1758835918768240 DO - 10.1177/1758835918768240 ID - Ko2018 ER - TY - JOUR AU - Wei, S. C. AU - Levine, J. H. AU - Cogdill, A. P. AU - Zhao, Y. AU - Anang, N. -. A. A. S. AU - Andrews, M. C. PY - 2017 DA - 2017// TI - Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade JO - Cell VL - 170 UR - https://doi.org/10.1016/j.cell.2017.07.024 DO - 10.1016/j.cell.2017.07.024 ID - Wei2017 ER - TY - JOUR AU - Zhang, Q. AU - Bi, J. AU - Zheng, X. AU - Chen, Y. AU - Wang, H. AU - Wu, W. PY - 2018 DA - 2018// TI - Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity JO - Nat Immunol VL - 19 UR - https://doi.org/10.1038/s41590-018-0132-0 DO - 10.1038/s41590-018-0132-0 ID - Zhang2018 ER - TY - JOUR AU - Bullock, M. AU - Ren, Y. AU - O’Neill, C. AU - Gill, A. AU - Aniss, A. AU - Sywak, M. PY - 2016 DA - 2016// TI - TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas JO - Clin Endocrinol VL - 85 UR - https://doi.org/10.1111/cen.12999 DO - 10.1111/cen.12999 ID - Bullock2016 ER - TY - JOUR AU - Polak, P. AU - Kim, J. AU - Braunstein, L. Z. AU - Karlic, R. AU - Haradhavala, N. J. AU - Tiao, G. PY - 2017 DA - 2017// TI - A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer JO - Nat Genet VL - 49 UR - https://doi.org/10.1038/ng.3934 DO - 10.1038/ng.3934 ID - Polak2017 ER - TY - JOUR AU - Haratani, K. AU - Hayashi, H. AU - Chiba, Y. AU - Kudo, K. AU - Yonesaka, K. AU - Kato, R. PY - 2018 DA - 2018// TI - Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer JO - JAMA Oncol. VL - 4 UR - https://doi.org/10.1001/jamaoncol.2017.2925 DO - 10.1001/jamaoncol.2017.2925 ID - Haratani2018 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617370.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617370.htm ID - ref151 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm613227.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm613227.htm ID - ref152 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604685.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604685.htm ID - ref153 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm590004.htm. Accessed 2 Nov2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm590004.htm ID - ref154 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577166.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577166.htm ID - ref155 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569366.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569366.htm ID - ref156 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm539646.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm539646.htm ID - ref157 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm528920.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm528920.htm ID - ref158 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501412.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501412.htm ID - ref159 ER - TY - STD TI - US Food & Drug Administration. http://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm474092.htm. Accessed 2 Nov 2018. UR - http://wayback.archive-it.org/7993/20170111064250/http:/www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm474092.htm ID - ref160 ER - TY - STD TI - US Food & Drug Administration. http://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm466576.htm. Accessed 2 Nov 2018. UR - http://wayback.archive-it.org/7993/20170111064250/http:/www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm466576.htm ID - ref161 ER - TY - STD TI - US Food & Drug Administration. http://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm465274.htm. Accessed 2 Nov 2018. UR - http://wayback.archive-it.org/7993/20170111064250/http:/www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm465274.htm ID - ref162 ER - TY - STD TI - US Food & Drug Administration. http://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm436566.htm. Accessed 2 Nov 2018. UR - http://wayback.archive-it.org/7993/20170111064250/http:/www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm436566.htm ID - ref163 ER - TY - STD TI - US Food & Drug Administration. http://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm427807.htm. Accessed 2 Nov 2018. UR - http://wayback.archive-it.org/7993/20170111064250/http:/www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm427807.htm ID - ref164 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm624659.htm . Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm624659.htm ID - ref165 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617471.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617471.htm ID - ref166 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610670.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610670.htm ID - ref167 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610572.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610572.htm ID - ref168 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577093.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577093.htm ID - ref169 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm ID - ref170 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm559300.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm559300.htm ID - ref171 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm558048.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm558048.htm ID - ref172 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm546893.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm546893.htm ID - ref173 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm526430.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm526430.htm ID - ref174 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm515627.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm515627.htm ID - ref175 ER - TY - STD TI - US Food & Drug Administration. http://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm478493.htm. Accessed 2 Nov 2018. UR - http://wayback.archive-it.org/7993/20170111064250/http:/www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm478493.htm ID - ref176 ER - TY - STD TI - US Food & Drug Administration. http://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm465650.htm. Accessed 2 Nov 2018. UR - http://wayback.archive-it.org/7993/20170111064250/http:/www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm465650.htm ID - ref177 ER - TY - STD TI - US Food & Drug Administration. http://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm412861.htm. Accessed 2 Nov 2018. UR - http://wayback.archive-it.org/7993/20170111064250/http:/www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm412861.htm ID - ref178 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm525780.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm525780.htm ID - ref179 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501878.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501878.htm ID - ref180 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm597248.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm597248.htm ID - ref181 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm ID - ref182 ER - TY - STD TI - US Food & Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm547965.htm. Accessed 2 Nov 2018. UR - https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm547965.htm ID - ref183 ER - TY - STD TI - US Food & Drug Administration. http://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm470061.htm. Accessed 2 Nov 2018. UR - http://wayback.archive-it.org/7993/20170111064250/http:/www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm470061.htm ID - ref184 ER -